Please login to the form below
Viralytics
This page shows the latest Viralytics news and features for those working in and with pharma, biotech and healthcare.
Transgene slumps as viral cancer therapy fails phase 3 trial
Boehringer Ingelheim made a big play in the category when it bought ViraTherapeutics for $236m last September, as did Merck with its $394m purchase of Viralytics, while Abbvie and Johnson &Johnson
Latest news
-
AZ invests more in IO with Transgene oncolytic virus deal
2018 also saw Merck &Co. acquire Australian firm Viralytics for $394m, suggesting growing belief in the oncolytic virus sector.
-
Boehringer bolts on another immuno-oncology company
2006. Other oncolytic virus candidates coming through the development pipelines from the likes of Viralytics, Oncolytics Biotech, AstraZeneca/Omnis and Genelux.
-
Morning brief: CAR-T competition hots up, Keytruda sales soar and more
CEO Kenneth Frasier has addressed these concerns by buying oncolytic virus specialists Viralytics for $394m, but is ruling out a sell-off of its animal health divison, or a mega-merger.
-
Merck buys cancer-killing virus firm Viralytics for $394m
Viralytics’ approach is to use a virus called coxsackievirus Type A21 - which seems to preferentially infect and kill cancer cells - to fight tumours. ... Merck has agreed to pay A$502m ($394m) for Sydney-based Viralytics, which will become a
-
Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal
For now these are the only two therapies of this type on the market, although there is a host of candidates coming through the development pipelines from the likes of Viralytics,
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Cancer immunotherapy: What's on the horizon?
Another virus – Viralytics’ Cavatak – showed promise in a phase I trial as a combination with Keytruda in melanoma, piquing Merck’s interest and prompting a $394m takeover deal earlier this year.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Moderna to launch Innovation and Technology Center in the UK
- Biogen and Happify Health team up to create digital platform for MS patients
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
- Research from Imperial College London shows single brain scan could diagnose Alzheimer’s disease
- VMLY&R wins two Grand Prix awards at Cannes Lions International Festival of Creativity 2022
- How digital health is changing the relationship between patients and health providers | OPEN Health
- Novartis endorses Kigali Declaration by investing $250m for tropical diseases
- Roche shares new positive Ocrevus data for MS patients
- Six UK universities receive grant for research into motor neurone disease
PMHub
McCann Health Medical Communications
We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
